Shares of DIAGENS-B (02526) surged over 20% during afternoon trading, reaching a peak of HK$507 and setting a fresh record high since its listing. At the time of writing, the stock was up 19.61% at HK$504.50, with turnover reaching HK$34.42 million.

The rally follows the announcement that Moderna, in collaboration with Merck, has achieved positive results from the world's first large-scale Phase III clinical trial for its personalized mRNA cancer vaccine, intismeran autogene. This development represents a landmark application of AI for Science (AI4S) in drug discovery, where the process begins with tumor DNA sequencing from patients and leverages AI to identify neoantigens and design mRNA sequences, ultimately producing customized vaccines tailored to each individual. This demonstrates that AI's role has evolved beyond mere assistance in the research phase, now encompassing the entire chain from sample analysis to candidate drug production.

Notably, with the continuous accumulation of model capabilities and platform ecosystem development, DIAGENS-B has officially entered a new phase as a "medical imaging AI research and production acceleration platform." As a scarce pure-play AI4S stock on the Hong Kong Stock Exchange, the company is expected to be included in the Hang Seng Composite Index in late August and formally added to the Stock Connect trading list around September 7. These inclusions are anticipated to significantly enhance the stock's liquidity and trading activity. With the convergence of the AI4S industry wave and substantial southbound capital allocation demand, DIAGENS-B holds considerable potential for valuation expansion.